DUBLIN--(BUSINESS WIRE)--The "CCR1 Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CCR1 Inhibitor development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for CCR1 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active CCR1 Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
Topics Covered
1. Report Introduction
2. CCR1 Inhibitor - Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. CCR1 Inhibitor Pipeline Products in Clinical Stages
6. CCR1 Inhibitor Pipeline Products in Non-Clinical Stages
7. Therapeutic Assessment - Active Products
8. Inactive Pipeline Product
Companies Featured
- ChemoCentryx
- Bristol-Myers Squibb
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/q53zsk/ccr1_inhibitor?w=4
